Overview of subcutaneous immunoglobulin 16.5% in primary and
secondary immunodeficiency diseases

J 2022

Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases

KOBAYASHI, R. H., Jiří LITZMAN, S. RIZVI, H. KREUWEL, S. HOELLER et. al.

Základní údaje

Originální název

Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases

Autoři

KOBAYASHI, R. H., Jiří LITZMAN (203 Česká republika, domácí), S. RIZVI, H. KREUWEL, S. HOELLER a S. GUPTA

Vydání

IMMUNOTHERAPY, London, FUTURE MEDICINE LTD, 2022, 1750-743X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.800

Kód RIV

RIV/00216224:14110/22:00125670

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2217/imt-2021-0313

UT WoS

000739331000001

Klíčová slova anglicky

Cutaquig; Gammanorm; primary immunodeficiency disease; subcutaneous administration of immunoglobulin; subcutaneous immunoglobulin

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 1. 2023 13:00, Mgr. Tereza Miškechová

Anotace

V originále

Lay abstract Primary immunodeficiency diseases, and select secondary immunodeficiency diseases, weaken the immune system, allowing infections and other health problems to occur more easily. Some patients require treatments to boost their immune system, such as immunoglobulin (IG) therapy, which can be either injected via a needle into a vein (intravenously) or inserted underneath the skin (subcutaneously; SCIG). The first instance of IG treatment for primary immunodeficiency disease was a 16.5% SCIG product given in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment. Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered subcutaneously in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG replacement therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment.

Citovat

KOBAYASHI, R. H., Jiří LITZMAN, S. RIZVI, H. KREUWEL, S. HOELLER a S. GUPTA. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. IMMUNOTHERAPY. London: FUTURE MEDICINE LTD, 2022, roč. 14, č. 4, s. 259-270. ISSN 1750-743X. Dostupné z: https://dx.doi.org/10.2217/imt-2021-0313.

@article{1847090,
   author = {Kobayashi, R. H. and Litzman, Jiří and Rizvi, S. and Kreuwel, H. and Hoeller, S. and Gupta, S.},
   article_location = {London},
   article_number = {4},
   doi = {http://dx.doi.org/10.2217/imt-2021-0313},
   keywords = {Cutaquig; Gammanorm; primary immunodeficiency disease; subcutaneous administration of immunoglobulin; subcutaneous immunoglobulin},
   language = {eng},
   issn = {1750-743X},
   journal = {IMMUNOTHERAPY},
   title = {Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases},
   url = {https://www.futuremedicine.com/doi/full/10.2217/imt-2021-0313?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 1847090
AU  - Kobayashi, R. H. - Litzman, Jiří - Rizvi, S. - Kreuwel, H. - Hoeller, S. - Gupta, S.
PY  - 2022
TI  - Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases
JF  - IMMUNOTHERAPY
VL  - 14
IS  - 4
SP  - 259-270
EP  - 259-270
PB  - FUTURE MEDICINE LTD
SN  - 1750743X
KW  - Cutaquig
KW  - Gammanorm
KW  - primary immunodeficiency disease
KW  - subcutaneous administration of immunoglobulin
KW  - subcutaneous immunoglobulin
UR  - https://www.futuremedicine.com/doi/full/10.2217/imt-2021-0313?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
N2  - Lay abstract Primary immunodeficiency diseases, and select secondary immunodeficiency diseases, weaken the immune system, allowing infections and other health problems to occur more easily. Some patients require treatments to boost their immune system, such as immunoglobulin (IG) therapy, which can be either injected via a needle into a vein (intravenously) or inserted underneath the skin (subcutaneously; SCIG). The first instance of IG treatment for primary immunodeficiency disease was a 16.5% SCIG product given in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment. Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered subcutaneously in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG replacement therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment.
ER  -

KOBAYASHI, R. H., Jiří LITZMAN, S. RIZVI, H. KREUWEL, S. HOELLER a S. GUPTA. Overview of subcutaneous immunoglobulin 16.5\%{} in primary and secondary immunodeficiency diseases. \textit{IMMUNOTHERAPY}. London: FUTURE MEDICINE LTD, 2022, roč.~14, č.~4, s.~259-270. ISSN~1750-743X. Dostupné z: https://dx.doi.org/10.2217/imt-2021-0313.

Podrobný výpis o publikaci